MDxHealth (NASDAQ:MDXH) Cut to “Hold” at Craig Hallum

Craig Hallum cut shares of MDxHealth (NASDAQ:MDXH) from a buy rating to a hold rating in a research report released on Friday morning, Marketbeat.com reports.

A number of other equities research analysts also recently commented on MDXH. Wall Street Zen raised MDxHealth to a “sell” rating in a research report on Saturday, August 15th. Lake Street Capital set a $3.00 target price on MDxHealth and gave the company a “buy” rating in a research note on Friday, August 14th. Weiss Ratings downgraded MDxHealth from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Finally, BTIG Research decreased their price target on MDxHealth from $4.00 to $2.00 and set a “buy” rating on the stock in a research note on Friday, August 21st. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $1.33.

MDxHealth Stock Performance

Shares of NASDAQ MDXH opened at $0.21 on Friday. The firm has a market cap of $10.23 million, a P/E ratio of -0.29 and a beta of 1.68. MDxHealth has a 1 year low of $0.19 and a 1 year high of $5.33. The firm’s 50 day moving average price is $0.64 and its 200 day moving average price is $0.91.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. The business had revenue of $27.21 million during the quarter, compared to analyst estimates of $26.14 million. As a group, equities analysts predict that MDxHealth will post -0.49 EPS for the current year.

Hedge Funds Weigh In On MDxHealth

Several institutional investors and hedge funds have recently bought and sold shares of MDXH. Squarepoint Ops LLC purchased a new position in MDxHealth during the second quarter worth approximately $82,000. Bank of America Corp DE boosted its holdings in shares of MDxHealth by 213.9% in the 1st quarter. Bank of America Corp DE now owns 43,492 shares of the company’s stock valued at $100,000 after purchasing an additional 29,638 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of MDxHealth by 21.8% during the 1st quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock valued at $701,000 after buying an additional 54,600 shares during the period. Finally, Perkins Capital Management Inc. grew its stake in shares of MDxHealth by 7.1% during the 1st quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock valued at $3,396,000 after buying an additional 97,500 shares during the period.

About MDxHealth

MDxHealth is a precision diagnostics company focused on improving the detection, diagnosis and management of cancer. The company develops and commercializes molecular and genomic tests designed to help physicians assess cancer risk, guide treatment decisions and monitor patients, with a primary focus on urological cancers.

Its product portfolio includes ConfirmMDx, a tissue-based test intended to help identify men who may have clinically significant prostate cancer after a prior negative biopsy; SelectMDx, a urine-based test that helps assess the likelihood of clinically significant prostate cancer; and ResolveMDx, a molecular test designed to support prostate cancer risk assessment.